Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Nachrichten zu bioMerieux SA
11.03.20
|
|
30.08.17
|
bioMérieux – First-Half 2017 Results (Businesswire)
|
31.07.17
|
|
27.07.17
|
|
20.07.17
|
bioMérieux – Second-Quarter 2017 Business Review (Businesswire)
|
20.04.17
|
|
19.01.17
|
|
10.11.16
|
|
20.10.16
|
|
17.10.16
|
bioMérieux: Lyme disease diagnostic tests (Businesswire)
|
11.10.16
|
FilmArray® Respiratory Panel EZ is CLIA waived by the FDA (Businesswire)
|
06.10.16
|
|
18.07.16
|
bioMérieux – Second-Quarter 2016 Business Review (Businesswire)
|
06.07.16
|
|
01.07.16
|
|
01.06.16
|
|
20.04.16
|
bioMérieux – First-Quarter 2016 Business Review (Businesswire)
|
08.04.16
|
|
22.03.16
|
|
02.03.16
|
bioMérieux – 2015 Financial Results (Businesswire)
|
25.02.16
|
|
26.01.16
|
|
21.01.16
|
bioMérieux – Fourth-Quarter 2015 Business Review (Businesswire)
|
12.01.16
|
|
05.01.16
|
|
14.12.15
|
|
04.11.15
|
|
22.10.15
|
|
09.10.15
|
|
31.08.15
|
bioMérieux – First-Half 2015 Results (Businesswire)
|
27.07.15
|
|
17.07.15
|
bioMérieux - First-Half 2015 Business Review (Businesswire)
|
23.04.15
|
bioMérieux - First-Quarter 2015 Business Review (Businesswire)
|
14.04.15
|
|
19.03.15
|
|
11.03.15
|
bioMérieux - 2014 Financial Results (Businesswire)
|
26.02.15
|
BioFire Receives FDA Clearance for the FilmArray® 2.0 System (Businesswire)
|
22.01.15
|
|
22.01.15
|
|
22.01.15
|
|
09.01.15
|
|
18.11.14
|
|
27.10.14
|
|
22.10.14
|
|
13.10.14
|
|
03.09.14
|
bioMérieux - First-Half 2014 Results (Businesswire)
|
21.08.14
|
|
23.07.14
|
|
17.07.14
|
bioMérieux - Second-Quarter 2014 Business Review (Businesswire)
|